News Daily News Apixaban Again Linked to Less Bleeding in AF Patients Michael O'Riordan October 31, 2022
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for September 2022 Shelley Wood October 03, 2022
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for August 2022 Shelley Wood September 01, 2022
News Opinion Editor's Corner ESC 2022 What’s Going to Be Hot at ESC 2022? Shelley Wood August 22, 2022
News Conference News HRS 2022 Racial/Ethnic Disparities in Anticoagulation Persist in Hospitalized AF Patients Todd Neale April 29, 2022
News Conference News ACC 2022 Managing AF Patients Undergoing PCI—Some Lingering Questions Michael O'Riordan April 12, 2022
News Daily News Fewer Diabetic Complications Seen When NOACs Given for AF L.A. McKeown February 22, 2022
News Daily News DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis L.A. McKeown January 20, 2022
News Daily News MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission Todd Neale December 29, 2021
News Daily News FDA Approves Two Additional Indications for Rivaroxaban in Children L.A. McKeown December 21, 2021
News Features When the Time Comes to Stop Oral Anticoagulation: Options and Obstacles Todd Neale September 28, 2021
News Daily News Long-term Anticoagulation After Unprovoked VTE: New Insights Shelley Wood September 13, 2021
News Opinion Editor's Corner ESC 2021 ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress Shelley Wood August 19, 2021
News Daily News Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t Shelley Wood August 04, 2021
News Conference News ACC 2021 ACTION: Full-Dose Rivaroxaban Doesn’t Help in Hospitalized COVID-19 Todd Neale May 17, 2021
News Daily News Dual Bests Triple Therapy in Nonvalvular AF Patients in RE-DUAL PCI Yael L. Maxwell April 09, 2021